- Home
- Products
Aliqopa(Copanlisib)
Aliqopa(Copanlisib)
- Medicine Name: Aliqopa
- Generic Name: Copanlisib
- Dosage Form & Strength: 60 mg lyophilized solid in a single-dose vial
- Manufactured By: Bayer Corporation
Aliqopa (Copanlisib) is an FDA-approved kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Recommended Dosage:
Aliqopa 60 mg is administered via intravenous infusion over 60 minutes on Days 1, 8, and 15 of a 28-day cycle (3 weeks on, 1 week off). Treatment should continue until disease progression or unacceptable toxicity is observed.
Severe infections, including fatal cases, have occurred. Monitor for symptoms and withhold treatment in cases of Grade 3 or higher infections.
Pneumocystis jiroveci pneumonia (PJP) risk exists; prophylaxis may be considered for high-risk patients.
Hyperglycemia (Grade 3/4) has been reported. Optimize blood glucose levels before treatment and adjust dosing as needed.
Hypertension (Grade 3) is possible; monitor blood pressure before and after infusions.
Non-infectious pneumonitis may occur. Evaluate patients showing respiratory symptoms such as dyspnea or hypoxia.
Neutropenia (Grade 3/4) may occur. Monitor complete blood counts weekly and adjust treatment accordingly.
Pregnancy risk: Copanlisib may cause fetal harm. Contraception is required during treatment and for 30 days post-therapy. Breastfeeding should also be avoided during this period.
To import Aliqopa (Copanlisib) through GlobalRareMeds, the following documents are mandatory:
- Valid prescription from a licensed physician
- Patient’s diagnostic reports
- Government-issued ID proof
Order Confirmation:
Orders are confirmed only after verification of prescription and, where applicable, import permits.
Aliqopa is a prescription-only oncology medication available under named-patient supply provisions in India and other countries.
GlobalRareMeds sources Aliqopa (Copanlisib) from certified distributors across the USA, Canada, Europe, and Australia.
Medicines are dispatched from our fulfillment center in Ambernath, Thane District, after prescription validation and pharmacist review. We ensure secure packaging, regulatory compliance, and prompt delivery across:
- India – Including cities such as Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Pune, Kolkata, and more.
- Global regions – Including SAARC countries and other locations subject to legal import requirements.
Contact for Orders & Pricing:
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name of Aliqopa?
A. The generic name is Copanlisib.
Q. Who manufactures Aliqopa?
A. Aliqopa is manufactured by Bayer HealthCare Pharmaceuticals Inc.
Q. Is Aliqopa FDA approved?
A. Yes, Aliqopa received FDA approval on September 14, 2017.
Q. What is the dosage form of Aliqopa?
A. Aliqopa is available as 60 mg lyophilized powder in a single-dose vial for intravenous use.
Q. What are common side effects of Aliqopa?
A. Common side effects include infections, high blood sugar, high blood pressure, fatigue, diarrhea, nausea, leukopenia, neutropenia, and thrombocytopenia.
Q. Can I use Aliqopa during pregnancy or breastfeeding?
A. No. Aliqopa may cause fetal harm. Pregnancy must be ruled out before starting therapy, and effective contraception is required. Breastfeeding should be avoided during and for 30 days post-treatment.
Q. What is the storage requirement for Aliqopa?
A. Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original packaging.
Q. How can I buy Aliqopa in India?
A. You can request Aliqopa through GlobalRareMeds with a valid prescription. We will assist with compliance and ensure genuine product delivery.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
